Corporate Venture Capital in Dutch Startups

Investment, commercial partnership and strategic dependence in Dutch venture deals

Corporate venture capital can look like a standard VC investment. A corporate investor subscribes for shares, negotiates investor rights and participates in a Dutch startup financing round.

But the commercial reality is often different. A corporate investor may also be a customer, supplier, distribution partner, licensee, development partner, data partner or future acquirer. That creates a dual relationship: shareholder on one side, commercial counterparty on the other.

For Dutch startups and scale-ups, corporate venture capital can be valuable. A strategic investor can provide capital, market access, technical expertise, commercial validation, distribution, data, industry knowledge and credibility.

But the same relationship can also create strategic dependence. Exclusivity, IP rights, data access, distribution arrangements, information rights, veto rights, ROFRs and change-of-control provisions can all affect future financing rounds and exit options.

This article is part of Venture Capital Insights: Dutch BV Financing, Investor Rights and Growth Company Governance.

Two relationships in one transaction

A corporate venture capital deal usually contains two relationships.

The first is the investment relationship. The corporate investor becomes a shareholder or investor in the Dutch BV. The investment documents may include preferred shares, liquidation preference, anti-dilution protection, information rights, pro rata rights, consent rights and transfer restrictions.

The second is the commercial relationship. The corporate may want to test the startup’s technology, become a launching customer, license software, distribute products, access data, run a pilot, develop new IP or reserve a future acquisition position.

These relationships must be coordinated but not confused.

If the commercial arrangements are hidden inside the shareholders’ agreement, they may be unclear and difficult to manage. If the commercial agreement is drafted separately without reference to the investment documents, the parties may miss how commercial rights affect valuation, governance and exit.

The key question is simple: what happens if the commercial partnership ends but the corporate remains a shareholder? And what happens if the corporate sells its shares but keeps commercial rights?

Exclusivity and strategic dependence

Corporate investors often ask for exclusivity. That may relate to a product, sector, geography, technology, distribution channel or customer group.

For the startup, exclusivity can make sense if it is matched by real value: committed revenue, distribution power, product validation, technical support or a significant investment.

But broad exclusivity can create strategic dependence. A startup may become locked into one corporate partner too early. Future customers may hesitate. Financial VC investors may view the startup as less independent. Strategic buyers may worry that key commercial rights already sit with someone else.

Exclusivity should therefore be limited. The agreement should define duration, territory, field, product scope, minimum commitments, performance milestones, termination rights and exceptions.

A startup should not give away future optionality in exchange for a limited investment or non-binding commercial promise.

IP ownership and licensing

IP is often the most important issue in a corporate venture capital deal.

The corporate may want access to software, know-how, algorithms, prototypes, data, patents, trade secrets or development results. The startup must protect its core technology and remain financeable and saleable.

The documents should clearly distinguish between background IP and newly developed IP. Background IP should normally remain with the party that owned it before the collaboration. Foreground IP must be allocated deliberately: to the startup, to the corporate, jointly, or through a license structure.

Licenses should also be specific. Are they exclusive or non-exclusive? Worldwide or limited? Perpetual or time-limited? Transferable or non-transferable? Royalty-free or paid? Limited to internal use or broader commercialization?

These choices affect future rounds. A new investor or buyer will ask whether the startup still owns and controls the technology that supports its valuation.

For Dutch BV financing mechanics, see also Implementing US-Style VC Terms in Dutch Venture Financings.

Data and development results

In AI, software, healthtech, fintech, climate tech and platform businesses, data can be as important as IP.

A corporate may want access to training data, customer data, usage data, product data, analytics, test results or jointly generated datasets. The startup must consider privacy, confidentiality, data ownership, data use rights, security, sector regulation and commercial reuse.

If the parties jointly develop a product, the agreement should state who can use the results. Can the startup sell the product to other customers? Can the corporate use the results across its group? Can either party use the data to train models? What happens after termination?

These points should not be postponed until after closing. Data and development rights can affect valuation, investor appetite and exit options.

Information rights and competitive sensitivity

Corporate investors often request information rights. That is normal in VC financings. Investors want financial information, budgets, KPIs, board materials and strategic updates.

With a corporate investor, information sharing can be more sensitive. The corporate may operate in the same industry, serve the same customers or compete with potential partners of the startup.

The shareholders’ agreement should therefore identify what information is shared, with whom inside the corporate group, under which confidentiality obligations and whether any clean team or restricted-access approach is needed.

The startup should avoid giving broad operational visibility to a corporate investor if that information could be used competitively.

Veto rights and future financing rounds

A corporate investor may ask for consent rights over major decisions. Some reserved matters are reasonable. A minority investor may need protection against issuing new shares, changing rights, selling key assets, amending the articles or entering into related-party transactions.

But corporate veto rights can be more problematic than financial investor veto rights. The corporate may have strategic incentives that do not align with the startup’s next financing round or exit.

For example, the corporate may want to block a financing by a competitor, prevent an exclusive partnership with another strategic party or influence product direction. If the veto rights are too broad, future VC investors may see the corporate as a blocking stakeholder.

Reserved matters should protect the corporate’s investment, not give it control over the startup’s commercial freedom.

ROFR, ROFN and change-of-control rights

Corporate venture capital documents often include a right of first refusal, right of first negotiation or change-of-control consent.

From the corporate’s perspective, this may be logical. It invests early and may want a future acquisition opportunity or protection against a competitor acquiring the startup.

From the startup’s perspective, these rights can damage exit dynamics. Potential acquirers may hesitate if a corporate investor has matching rights, negotiation rights or approval rights. This is especially sensitive if the corporate is itself a likely bidder or competitor.

These rights should be carefully limited. The documents should address trigger events, timing, procedure, confidentiality, exceptions, duration and interaction with drag-along, tag-along and board approvals.

The goal is to give the corporate a fair strategic position without making the startup harder to sell.

Interaction with Dutch BV governance

A Dutch corporate venture capital investment must be implemented through Dutch BV documentation.

Depending on the structure, the rights may be set out in the investment agreement, shareholders’ agreement, articles of association, board regulations, side letter and commercial agreements.

Not all rights belong in the same place. Share class rights, voting rights and certain governance arrangements may need to be reflected in the articles. Commercial arrangements usually belong in separate contracts. Investor-specific arrangements may be placed in the shareholders’ agreement or side letter, but should not conflict with mandatory Dutch corporate mechanics.

The Dutch BV structure should remain understandable. Future investors and buyers should be able to see which rights are corporate law rights, which are contractual investor rights and which are commercial business arrangements.

Practical conclusion

Corporate venture capital can be highly valuable for Dutch startups and scale-ups. The right corporate investor can provide much more than capital: access to customers, distribution, technical knowledge, market credibility and a possible future exit route.

But the dual role of shareholder and commercial partner must be documented carefully.

Founders should ask not only how much the corporate invests, but also which strategic rights the startup gives away. Investors should ask whether the commercial arrangements support the company’s growth or restrict its independence. International counsel should ensure that US-style or UK-style VC terms are translated into Dutch BV documentation and aligned with the commercial agreements.

A strong CVC deal creates strategic value without closing off future financing or exit routes.

FAQ

What is corporate venture capital?
Corporate venture capital is an investment by a strategic company in a startup or scale-up, often combined with commercial cooperation, access to technology, distribution or future acquisition interest.

Why is CVC different from a financial VC investment?
Because the corporate investor may also be a customer, supplier, licensee, distribution partner, data partner or potential acquirer.

Can exclusivity harm a Dutch startup?
Yes. Broad exclusivity can limit future customers, investors and buyers. It should be limited by scope, time, territory, product and performance commitments.

Who should own IP developed with a corporate partner?
That must be expressly agreed. Background IP, newly developed IP, licenses and data rights should be separated clearly.

Can CVC rights affect a future exit?
Yes. ROFRs, ROFNs, change-of-control rights, exclusive licenses and broad veto rights can discourage potential buyers or complicate an auction process.

About Dirk de Waard

Dirk de Waard is a Dutch corporate, M&A and venture capital lawyer and partner at Venture Lawyers in Amsterdam. He advises founders, startups, scale-ups, VC funds, corporate investors and strategic parties on Dutch venture capital, corporate venture capital, shareholders’ agreements, IP and data arrangements, commercial partnerships, governance and exit rights.

ViottaLaw is Dirk’s personal insights platform. Legal services are provided through Venture Lawyers.

Structuring a corporate venture capital deal?

A corporate venture capital transaction should separate investment rights from commercial cooperation, while making sure both work together. Exclusivity, IP, data, distribution, information rights, veto rights and exit provisions should be clear before signing.

Dirk de Waard advises startups, scale-ups and corporate investors on Dutch CVC transactions. Contact Dirk at dirk.dewaard@viottalaw.com to structure a corporate venture capital investment or strategic partnership in the Netherlands.